Min Young Lee
YOU?
Author Swipe
View article: Low neutrophil-to-lymphocyte ratio identifies secondary polycythemia in patients with erythrocytosis
Low neutrophil-to-lymphocyte ratio identifies secondary polycythemia in patients with erythrocytosis Open
The neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammation, may assist in differentiating polycythemia vera (PV) from secondary polycythemia (SP), especially when access to JAK2 mutation testing is limited due to co…
View article: Partial Deletion of the Carboxyl‐Terminal Signal Sequence of the Cellular Prion Protein Alters Protein Expression via Endoplasmic Reticulum–Associated Degradation
Partial Deletion of the Carboxyl‐Terminal Signal Sequence of the Cellular Prion Protein Alters Protein Expression via Endoplasmic Reticulum–Associated Degradation Open
Cellular prion protein (PrP C ) is a glycoprotein tethered to the plasma membrane via a GPI‐anchor, and it plays a crucial role in prion diseases by undergoing conformational change to PrP Sc . To generate a knock‐in (KI) mouse model expre…
View article: Data from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Data from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
The tumor microenvironment in solid tumors contains myeloid cells that modulate local immune activity. Stimulator of IFN gene (STING) signaling activation in these myeloid cells enhances local type-I IFN production, inducing an innate immu…
View article: Supplementary Table 3 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 3 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Antibodies Used in Murine Receptor Occupancy Flow Panel
View article: Supplementary Figure 5 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 5 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Gating Strategy for Monocyte Activation in PBMCs
View article: Supplementary Figure 11 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 11 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Binding Curves Demonstrate Species Specificity for antibody portions of TAK-500 and mTAK-500
View article: Supplementary Figure 1 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 1 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Analysis of TAK-500 iADC.
View article: Supplementary Figure 10 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 10 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Gating Strategy for Murine Macrophage/Dendritic Cell Panel
View article: Supplementary Table 6 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 6 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
T Cell Panel for Evaluating Dissociated Tumor Cells
View article: Supplementary Figure 7 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 7 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Gating Strategy for Evaluating CCR2 in Dissociated Tumor Cells: Monocyte Panel
View article: Supplementary Table 2 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 2 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Example Conditions for generating QTOF- liquid chromatography/mass spectrometry (LCMS) spectra
View article: Supplementary Figure 12 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 12 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Complete loss of receptor-mediated TAK-500 and mTAK-500 activity observed on human and murine peripheral blood monocytes lacking cell surface CCR2 expression
View article: Supplementary Figure 13 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 13 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Evaluation of CCR2 expression levels and the impact of TAK-500 treatment on T and NK cell activation and cytokine production in vitro.
View article: Supplementary Figure 9 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 9 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Gating Strategy for Murine T Cell Panel
View article: Figure 4 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Figure 4 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
mTAK-500 shows dose-dependent induction of innate and adaptive immunity in an MC38 tumor–bearing mouse model. Data shown represent the mean from five mice per group per timepoint. Experiment was performed at least twice with consistent res…
View article: Figure 6 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Figure 6 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Spatially resolved and quantitative analysis of CCR2 in human NSCLC, PDAC, and CRC. A, Representative multicolor fluorescence micrographs of NSCLC cases with high (left) and low CCR2 protein expression (right). The color code for the marke…
View article: Supplementary Figure 8 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 8 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Gating Strategy for Evaluating T and NK Cell Activation
View article: Supplementary Table 1 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 1 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Cell Lines Utilized Within These Studies
View article: Supplementary Table 5 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 5 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Antibodies Used in Monocyte Activation Flow Panel
View article: Supplementary Figure 6 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 6 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Gating Strategy for Evaluating CCR2 in Dissociated Tumor Cells: T Cell Panel
View article: Figure 2 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Figure 2 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
TAK-500 drives activation of monocytes and induces type-I IFN response in vitro.A, Evaluation of classical monocyte frequency (left), monocyte activation (middle), and CCR2 expression (right) in PBMCs treated with TAK-500 for 24 hours. Dat…
View article: Supplementary Figure 14 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 14 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
mTAK-500 induced efficacy requires CD8+ T cell mediated adaptive immunity.
View article: Figure 5 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Figure 5 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
mTAK-500 shows durable enhanced efficacy and increased activation of innate and adaptive immune responses when combined with anti–PD-1 or radiation. A, Antitumor effect of mTAK-500 with and without αPD-1 therapy in C57BL/6 mice bearing MC3…
View article: Supplementary Table 13 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 13 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Pharmacokinetic Parameters of Total Ab, Conjugated Dazostinag, and Deconjugated Dazostinag in Female C57BL/6 Mice Bearing MC38 Tumors After Intravenous Administration of mTAK-500 at 2, 10, and 50 µg/kg
View article: Supplementary Table 11 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 11 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
TAK-500 enhances type I IFN response in THP1 cells expressing human CCR2
View article: Supplementary Table 9 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 9 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Antibodies Used in T Cell Panel
View article: Supplementary Table 14 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 14 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Clinicopathologic characteristics of NSCLC, CRC and PDAC cohorts
View article: Figure 3 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Figure 3 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
mTAK-500 shows dose-dependent efficacy and induction of cytokine release in MC38 tumor–bearing mouse models. A, Antitumor effect of mTAK-500 in C57BL/6 mice bearing MC38 tumors. Data shown represent the MTVs from eight mice per group. B, C…
View article: Supplementary Figure 15 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Figure 15 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Evaluation of CCR2 expression in intratumoral mMDSCs within syngeneic tumor bearing mouse models via flow cytometry correlated with the antitumor response of those models to mTAK-500. Models evaluated include C1498, B16F10, MC38, H22, CT26…
View article: Supplementary Table 7 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Supplementary Table 7 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500 Open
Monocyte Panel for Evaluating Dissociated Tumor Cells